Quince Therapeutics：LAM-001用于PH-ILD的2b期数据预计于2028年第一季度公布

来源摘录

EX-99.4 3 d163930dex994.htm EX-99.4 EX-99.4 Exhibit 99.4 BUSINESS Our Company We are a clinical-stage biopharmaceutical company developing a novel disease modifying therapeutic to address the significant unmet medical need associated with pulmonary disorders with few, if any, treatment options available. On May 18, 2026, we completed the acquisition of Orphai Therapeutics, a clinical-stage biopharmaceutical company developing therapies to treat serious, underserved pulmonary disorders. The acquisition brought into our pipeline Orphai’s lead asset, LAM-001, a proprietary investigational inhaled dry powder formulation of rapamycin whose differentiated characteristics may permit treatment of conditions associated with dysfunctional mammalian target of rapamycin (“mTOR”) activity that cann

SEC 8-K

该资产的更多信息

2026年10月19日

12:49

IRIRLAIRulya Therapeutics Inc.

IRulya 更新 LAM-001 用于 PH-ILD、BOS 和 SAPH 的 2 期时间表

临床试验登记变更SEC 8-K

2026年10月15日

15:20

QNCXQuince Therapeutics, Inc.

LAM-001 · NCT05798923 注册更新

临床试验登记变更ClinicalTrials.gov

2026年10月9日

11:59

QNCXQuince Therapeutics, Inc.

IRulya (IRLA) 重新启动，LAM-001 II 期读出数据预计在 BOS（2027 年第 1 季度）、PH-ILD（2028 年第 1 季度）、SAPH（2028 年第 4 季度）

临床试验登记变更SEC 8-K

2026年9月29日

15:22

QNCXQuince Therapeutics, Inc.

LAM-001 · NCT05798923 注册更新

临床试验登记变更ClinicalTrials.gov